Imunon, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand Imunon’s performance this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Imunon is a clinical-stage biotech company. Think of them as a laboratory startup: they are developing high-potential medical treatments but aren't selling anything yet. Since they have no products on pharmacy shelves, they generate no sales revenue. Instead, they focus on two main technology platforms:

• TheraPlas: A DNA-based platform that turns the body’s own cells into "factories" to produce cancer-fighting proteins directly at the tumor site.
• PlaCCine: A platform using that same DNA technology to develop vaccines for infectious diseases, aiming for faster manufacturing and better stability than traditional vaccines.

2. How are they performing?

Since they don't sell products, we measure performance by their clinical trial progress. Their lead project, IMNN-001 (an immunotherapy for ovarian cancer), just cleared a major hurdle.

They recently finished their "OVATION 2" Phase 2 study with encouraging results. Patients treated with IMNN-001 lived a median of 27.1 months, compared to 14.1 months for those receiving standard chemotherapy alone. For patients also taking a common maintenance drug, the survival benefits were even stronger. The FDA has granted this treatment "Fast Track" status. This clears the way for Imunon to start a Phase 3 trial—the final, critical stage of testing before they can apply to sell the drug.

3. Financial Health: The "Cash Burn" Reality

Imunon is in a classic "cash-burn" phase. For the year ending December 31, 2025, the company lost $22.4 million, mostly due to $13.8 million in research costs. With no steady income, they rely entirely on raising money from investors to keep the labs running.

To stay afloat, they frequently sell new shares. As of March 30, 2026, they had about 3.9 million shares outstanding. With $12.5 million in cash at the end of 2025, the company expects to run out of money by the second half of 2026. They will need to raise more cash to finish their expensive Phase 3 trial.

4. The Big Risks

If you are considering investing, keep these two risks in mind:

• Dilution: Every time Imunon issues new shares to pay for trials, your "slice of the pie" gets smaller. Because Phase 3 trials cost tens of millions of dollars, the company will likely sell more shares. This reduces the value of your existing ownership.
• "All-or-Nothing" Science: The company’s value depends entirely on its clinical trials. Phase 3 trials are large, complex, and subject to strict scrutiny. If the final trial fails to prove the drug works, the company has no other products to fall back on. This would likely cause the share price to crash.

5. The Bottom Line

Imunon is a high-risk, high-reward bet. You aren't buying a company with steady sales; you are buying a seat at the table for a scientific experiment. They have reached a major milestone by moving their lead cancer treatment into final testing.

Before you decide: Ask yourself if you are comfortable with the volatility of a company that relies on future fundraising and successful clinical outcomes. If you are looking for stability, this is likely not the right fit; if you are looking for exposure to potential breakthroughs in cancer treatment, Imunon is currently at a pivotal transition point.